Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Shirish Gadgeel, Alice T. Shaw, Fabrice Barlesi, Lucio Crinò, James Chih Hsin Yang, Anne Marie C. Dingemans, Dong Wan Kim, Filippo De Marinis, Mathias Schulz, Shiyao Liu, Ravindra Gupta, Ahmed Kotb, Sai Hong Ignatius Ou

Research output: Contribution to journalArticle

Abstract

Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalBritish Journal of Cancer
Volume118
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • alectinib
  • ALK positive
  • central nervous system
  • cumulative incidence rates
  • disease progression
  • non-small-cell lung cancer
  • phase II

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC'. Together they form a unique fingerprint.

  • Cite this

    Gadgeel, S., Shaw, A. T., Barlesi, F., Crinò, L., Yang, J. C. H., Dingemans, A. M. C., Kim, D. W., De Marinis, F., Schulz, M., Liu, S., Gupta, R., Kotb, A., & Ou, S. H. I. (2018). Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. British Journal of Cancer, 118(1), 38-42. https://doi.org/10.1038/bjc.2017.395